A peptide antigen derived from EGFR T790M is immunogenic in nonsmall cell lung cancer

By  

International Journal of Oncology, Vol. 46, Iss. 2, 2015-01 ,pp. : 497-504

Spandidos Publications

Access to resources Recommend Favorite

The Role of Irreversible EGFR Inhibitors in the Treatment of Non-Small Cell Lung Cancer: Overcoming Resistance to Reversible EGFR Inhibitors

By Belani Chandra P.  

Cancer Investigation, Vol. 28, Iss. 4, 2010-04 ,pp. : 413-423

Informa Healthcare

Access to resources Recommend Favorite

Combined Treatment with Epimedium koreanum Nakai Extract and Gefitinib Overcomes Drug Resistance Caused by T790M Mutation in Non-Small Cell Lung Cancer Cells

By Song Jie   Zhong Rongling   Huang Houcai   Zhang Zhenhai   Ding Dongmei   Yan Hongmei   Sun E   Jia Xiaobin  

Nutrition and Cancer, Vol. 66, Iss. 4, 2014-05 ,pp. : 682-689

Routledge Ltd

Access to resources Recommend Favorite

Knockdown of the Bcl-2 gene increases sensitivity to EGFR tyrosine kinase inhibitors in the H1975 lung cancer cell line harboring T790M mutation

By                    

International Journal of Oncology, Vol. 42, Iss. 6, 2013-01 ,pp. : 2094-2102

Spandidos Publications

Access to resources Recommend Favorite

Combined inhibition of the EGFR and mTOR pathways in EGFR wild-type non-small cell lung cancer cell lines with different genetic backgrounds

By Huang Yu   Chen Yu   Mei Qin   Chen Yuan   Yu Shiying   Xia Shu  

Oncology Reports, Vol. 29, Iss. 6, 2013-06 ,pp. : 2486-2492

Spandidos Publications

Access to resources Recommend Favorite